Characterization of Ewing sarcoma associated cancer/testis antigens

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Ewing family of tumors (EFT) have a poor prognosis, necessitating novel therapeutic strategies.
• Immunotherapy, particularly targeting cancer/testis antigens (CTA), offers a promising avenue for EFT treatment.
• EFT are defined by specific chromosomal rearrangements involving TET and ETS family proteins, creating unique onco-fusion proteins.

Purpose of the Study:

• To identify novel EFT-specific CTA for immunotherapy.
• To investigate the role of TET-ETS oncoprotein in CTA expression.
• To evaluate the potential of identified CTA as targets for cytotoxic T-lymphocyte (CTL) therapy.

Main Methods:

• Analysis of microarray datasets from the Gene Expression Omnibus (GEO) database for EFT and normal tissues.
• Examination of GEO datasets from transgenic mesenchymal stem cells to assess the impact of TET-ETS on CTA expression.
• In vitro assays using CTLs specific for identified CTA peptides against HLA-A2 positive EFT cells.

Main Results:

• Lipase I (LIPI), a membrane-associated phospholipase A1-β, was identified as a CTA with high specificity for EFT.
• TET-ETS fusion proteins influence the expression of specific CTA in EFT.
• CTLs targeting LIPI-derived peptides (LDYTDAKFV and NLLKHGASL) demonstrated efficacy in lysing HLA-A2 positive EFT cells in vitro.

Conclusions:

• LIPI is a potential tumor-specific antigen for EFT immunotherapy.
• Targeting LIPI with CTLs represents a viable strategy for EFT treatment.
• Further investigation into LIPI and other CTA could advance EFT immunotherapy.